THE EFFECT OF 2 NEW GLUCOSIDASE INHIBITORS ON BLOOD-GLUCOSE IN HEALTHY-VOLUNTEERS AND IN TYPE-II DIABETICS

被引:6
作者
FEDERLIN, KF
MEHLBURGER, L
HILLEBRAND, I
LAUBE, H
机构
来源
ACTA DIABETOLOGICA LATINA | 1987年 / 24卷 / 03期
关键词
D O I
10.1007/BF02732040
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:213 / 221
页数:9
相关论文
共 12 条
[1]  
CAUDERAY M, 1985, METABOLISM, V35, P472
[2]   EFFECTS OF 2 NEW ALPHA-GLUCOSIDASE INHIBITORS ON GLYCEMIC CONTROL IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS [J].
DIMITRIADIS, G ;
RAPTIS, S ;
RAPTIS, A ;
HATZIAGELAKI, E ;
MITRAKOU, A ;
HALVATSIOTIS, P ;
LADAS, S ;
HILLEBRAND, I .
KLINISCHE WOCHENSCHRIFT, 1986, 64 (09) :405-410
[3]   THE EFFECT OF NEW ALPHA-GLUCOSIDASE INHIBITORS (BAY M-1099 AND BAY O-1248) ON MEAL-STIMULATED INCREASES IN GLUCOSE AND INSULIN LEVELS IN MAN [J].
HILLEBRAND, I ;
BOEHME, K ;
GRAEFE, KH ;
WEHLING, K .
KLINISCHE WOCHENSCHRIFT, 1986, 64 (08) :393-396
[4]  
HILLEBRAND I, 1986, COMMUNICATION
[5]   EFFECT OF AN ALPHA-GLUCOSIDASE INHIBITOR (BAY M 1099) ON POSTPRANDIAL BLOOD-GLUCOSE AND INSULIN IN TYPE-II DIABETICS [J].
JOUBERT, PH ;
BAM, WJ ;
MANYANE, N .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (02) :253-255
[6]   THE EFFECT OF A 1-DEOXYNOJIRIMYCIN DERIVATIVE ON POST-PRANDIAL BLOOD-GLUCOSE AND INSULIN LEVELS IN HEALTHY BLACK AND WHITE VOLUNTEERS [J].
JOUBERT, PH ;
VENTER, CP ;
JOUBERT, HF ;
HILLEBRAND, I .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (06) :705-708
[7]  
KATSILAMBROS N, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1136
[8]  
PULS W, 1984, INT J OBESITY, V8, P181
[9]   ALPHA-GLUCOSIDASE INHIBITORS - NEW COMPLEX OLIGOSACCHARIDES OF MICROBIAL ORIGIN [J].
SCHMIDT, DD ;
FROMMER, W ;
JUNGE, B ;
MULLER, L ;
WINGENDER, W ;
TRUSCHEIT, E ;
SCHAFER, D .
NATURWISSENSCHAFTEN, 1977, 64 (10) :535-536
[10]   EFFECTS OF THE ALPHA-GLUCOSIDASE INHIBITOR 1-DESOXYNOJIRIMYCIN (BAY M-1099) ON POSTPRANDIAL BLOOD-GLUCOSE, SERUM-INSULIN AND C-PEPTIDE LEVELS IN TYPE-II DIABETIC-PATIENTS [J].
SCHNACK, C ;
ROGGLA, G ;
LUGER, A ;
SCHERNTHANER, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (04) :417-419